Phaseline

Companies › NexThera

NexThera: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NT-101 ophthalmic solution
Pigment epithelium-derived factor (PEDF) in type I atelocollagen formulation
PEDFPhase 2Wet Age Related Macular DegenerationFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07811726NT-101 ophthalmic solutionPhase 2Wet Age Related Macular DegenerationOphthalmologyFeb 2028

Targets

PEDF (1)

Companies with the same targets

–

Companies built like this

Regenerative Patch Technologies Price Vision Group jCyte NovaSight Emmecell

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.